Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Want to see CRBP full AI Analyst Report?
CRBP Stock Chart & Stats
$10.59
-$0.10(-0.79%)
At close: 4:00 PM EST
$10.59
-$0.10(-0.79%)
Day’s Range― - ―
52-Week Range$6.72 - $20.56
Previous CloseN/A
Volume39.58K
Average Volume (3M)503.64K
Market Cap
$153.04M
Enterprise Value$76.07M
Total Cash (Recent Filing)$138.60M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 11, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding18,527,796
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-510.54
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$38.44Price Target Upside263.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.64
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Sizable EquityA very low debt-to-equity ratio and meaningful equity cushion provide durable financial flexibility to fund multi-year clinical programs and absorb operational losses. This reduces near-term refinancing pressure, supports partnership negotiations, and limits solvency risk while registrational trials proceed.
CRB-701: Compelling Phase 1/2 Data And FDA AlignmentRobust early response rates and FDA agreement on single randomized registrational trials materially de-risk CRB-701's clinical pathway. A clear regulatory path and randomized TEMPO-1 start increase the probability of accelerated approval potential, improving long-term commercial prospects and partner interest if durability and survival endpoints validate.
Strengthened Biz-dev And Governance TeamHiring an experienced CBO and adding a commercial oncology director enhances the firm's capacity to secure partnerships, licensing deals, and commercialization planning. Better business development and governance reduce execution risk through registrational to potential launch phases and improve strategic deal-making resilience.
Bears Say
Pre-revenue With Widening LossesOperating without product revenue and materially widening net losses mean the company depends on external funding or milestone-based partnerships. Persistent losses erode equity over time and create a structural profitability gap that must be closed by successful approvals or durable commercial agreements to sustain the business.
High And Rising Cash BurnEscalating negative operating and free cash flow creates ongoing financing needs to complete registrational trials. Persistent burn increases dilution risk or forces asset sales/partnering under time pressure, constraining strategic optionality and potentially delaying trial timelines if additional funding terms are unfavorable.
Clinical Execution & Leadership Transition RiskThe departure of the Chief Medical Officer at a pivotal shift to registrational-stage development introduces execution risk around protocol finalization, regulatory interactions, and trial oversight. Leadership turnover during critical trial start-up increases the chance of delays or operational missteps that can affect long-term program timelines.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $6.72 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $153.04M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 51 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.26.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 18,527,796 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went up 3.533%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.44 (263.03% Upside)
$38.44 (263.03% Upside)
Hedge Fund Trend
Decreased
By 15.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $101.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 31.9%
Last 30 Days ▲ 31.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.19%
12-Months-Change
Fundamentals
Return on Equity
-70.89%
Trailing 12-Months
Asset Growth
3.25%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating immune modulators designed to combat immuno-oncology and various fibrotic conditions. Its pipeline includes lenabasum, an orally administered small molecule. This compound selectively activates cannabinoid receptor type 2 (CB2) and is currently undergoing Phase II clinical trials for the treatment of systemic lupus erythematosus. The company is also advancing CRB-601, an anti-integrin monoclonal antibody (mAb) engineered to inhibit the activation of transforming growth factor ß (TGFß), which it is developing for both cancer and fibrotic indications. Another key asset is CRB-602, an anti-avß6/avß8 mAb designed to block TGFß activation, specifically for addressing fibrotic diseases. Beyond these, Corbus is pursuing a cannabinoid receptor type 1 inverse agonist program. This broad-spectrum initiative targets several conditions, including metabolic disorders such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; various fibrotic diseases, like lung, cardiac, renal, and liver fibrosis; and other ailments, including ascites, cognitive impairments, Prader-Willi syndrome, and smoking cessation. In terms of collaborations, Corbus has a licensing agreement with Jenrin Discovery, LLC. This partnership grants them rights to develop and commercialize products, encompassing Jenrin's extensive library of approximately 600 compounds, alongside numerous issued and pending patent applications. Established in 2009, the company's headquarters are located in Norwood, Massachusetts.
CRBP Stock 12 Month Forecast
Average Price Target
$38.44
▲(263.03% Upside)
Technical Analysis
Ownership Overview
15.58% Insiders
5.18% Mutual Funds
39.74% Other Institutional Investors
33.81% Public Companies and
Individual Investors